How to Evaluate CDMOs for Complex Chemistry APIs: A Buyer's Guide
Selecting a contract development and manufacturing organization (CDMO) for complex chemistry APIs is one of the highest-stakes decisions a pharmaceutical company makes. The wrong partner can delay clinical timelines, compromise product quality or create regulatory risk that surfaces years after the initial engagement.
Complex chemistries—including high-pressure hydrogenation, carbonylation, organometallic reactions and highly potent API (HPAPI) synthesis—require specialized equipment, deep process expertise and robust quality systems. Not every CDMO can deliver at the scale and consistency required for late-phase clinical supply and commercial manufacturing.
This guide provides a structured framework for evaluating CDMO partners across five critical dimensions: technical capabilities, scale-up readiness, quality systems, regulatory experience and commercial track record.
1. Technical Capabilities: Can They Handle Your Chemistry?
The first filter in any CDMO evaluation is technical fit. Complex chemistry APIs often require specialized unit operations that not all manufacturers can support.
Key questions to ask:
Does the CDMO have experience with your specific reaction types—such as Grignard reactions, cyanation, Friedel-Crafts chemistry, biocatalysis or heterogeneous/homogeneous catalytic reactions?
What reactor materials and sizes are available? Glass-lined and Hastelloy reactors ranging from 1,000 L to 12,000 L provide flexibility for different process requirements.
Can the site support high-pressure hydrogenation and carbonylation? These reactions require specialized equipment and safety protocols.
What potency levels can the facility handle? For HPAPIs, confirm the site is rated for OEB4 or OEB5 compounds and has appropriate containment infrastructure such as glove boxes for powder charging and load-out.
What analytical capabilities are on-site? Full-service analytical support—including HPLC, UPLC, GC, ICP-OES, ICP-MS, GC-MS, LC-MS, FT-IR, powder X-ray diffraction and particle size analysis—reduces dependency on external labs and accelerates decision-making.
A CDMO with a broad chemistry toolkit and flexible equipment trains can adapt to process changes during development without requiring a site transfer.
2. Scale-Up Readiness: Can They Move from Lab to Commercial?
Many CDMOs can execute a process at lab scale. Fewer can reliably scale that process to commercial volumes while maintaining yield, purity and cycle time.
Evaluate scale-up readiness by examining:
Pilot plant capabilities: Does the CDMO have dedicated technical operations teams and pilot plant equipment for process optimization, troubleshooting and tech transfer support?
Equipment range: A site with reactors from 0.5 L to 12,000 L can support seamless progression from development through commercial manufacturing.
Tech transfer track record: Ask how many late-phase and commercial tech transfers the site has completed. A CDMO with 20+ completed tech transfers has demonstrated the ability to onboard complex processes from external sponsors.
Process validation approach: Understand how the CDMO approaches process performance qualification (PPQ). A structured approach—including impurity fate-purge studies, FMEA-based risk assessments and demonstration batches—reduces the risk of validation failures.
Scale-up is where many CDMO relationships fail. Prioritize partners with a documented history of successful commercial transitions.
3. Quality Systems: Are They Built for Global Compliance?
Quality failures in API manufacturing can result in batch rejections, regulatory warning letters and supply disruptions. A CDMO's quality systems must be robust enough to withstand scrutiny from regulators worldwide.
Key quality evaluation criteria:
Regulatory inspection history: Has the site been inspected by FDA, EMA and other major regulatory agencies? What were the outcomes?
Global filing experience: A CDMO approved to supply in 60+ countries has demonstrated the ability to meet diverse regulatory requirements.
Analytical method validation: Confirm the CDMO can support method development, validation, transfer and stability testing in-house.
Change control and deviation management: Ask how the site handles process changes, deviations and investigations. A mature quality system will have clear escalation pathways and root cause analysis protocols.
Raw material supplier qualification: Understand how the CDMO evaluates and qualifies raw material suppliers. Weak upstream controls can introduce variability into your process.
Quality is not a differentiator—it is a baseline requirement. Any CDMO that cannot demonstrate a strong quality track record should be disqualified early in the evaluation process.
4. Regulatory Experience: Can They Support Global Filings?
Regulatory starting material (RSM) selection, control strategy development and CMC documentation are critical to first-cycle approval. A CDMO with deep regulatory experience can help sponsors avoid common pitfalls.
Evaluate regulatory capabilities by asking:
Does the CDMO apply ICH Q11 principles to RSM selection?
Can they support backup or push-back RSMs if agencies request an alternative?
Do they have experience with mutagenic impurity and nitrosamine risk assessments?
Can they support global filing strategies that anticipate regional differences between FDA, EMA and other agencies?
A CDMO that treats regulatory strategy as an afterthought will create problems at the submission stage. Look for partners that integrate regulatory thinking into process development from the start.
5. Commercial Track Record: Have They Done This Before?
The most reliable predictor of future performance is past performance. A CDMO with a strong commercial track record has proven it can deliver at scale, on time and within specification.
Key indicators of commercial readiness:
Number of commercial APIs: A CDMO with 8+ commercial APIs has demonstrated the ability to support products through launch and lifecycle management.
Supply chain resilience: Does the CDMO have multiple manufacturing sites or redundant capacity? Geographic diversification reduces single-point-of-failure risk.
Long-term partnership orientation: An embedded CDMO—one that operates within a larger pharmaceutical company—often has access to broader technical resources, established quality systems and a business model that supports long-term relationships rather than capacity-filling.
Commercial manufacturing is not the time to discover that your CDMO lacks the operational discipline to deliver consistently. Prioritize partners with a proven track record.